CA2470668C - 5ht4 partial agonist pharmaceutical compositions - Google Patents
5ht4 partial agonist pharmaceutical compositions Download PDFInfo
- Publication number
- CA2470668C CA2470668C CA2470668A CA2470668A CA2470668C CA 2470668 C CA2470668 C CA 2470668C CA 2470668 A CA2470668 A CA 2470668A CA 2470668 A CA2470668 A CA 2470668A CA 2470668 C CA2470668 C CA 2470668C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- tegaserod
- mixture
- weight
- disintegrant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 239000004031 partial agonist Substances 0.000 title description 8
- 229960002876 tegaserod Drugs 0.000 claims abstract description 26
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 claims abstract description 25
- 239000007884 disintegrant Substances 0.000 claims abstract description 20
- 239000000314 lubricant Substances 0.000 claims abstract description 18
- 150000003839 salts Chemical group 0.000 claims abstract description 7
- 239000007787 solid Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 23
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 18
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 15
- 239000003085 diluting agent Substances 0.000 claims description 14
- 229960000913 crospovidone Drugs 0.000 claims description 13
- 238000007907 direct compression Methods 0.000 claims description 13
- 239000008101 lactose Substances 0.000 claims description 13
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 13
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 13
- 239000011230 binding agent Substances 0.000 claims description 12
- 239000007921 spray Substances 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 238000005461 lubrication Methods 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- 238000007906 compression Methods 0.000 claims description 4
- 230000006835 compression Effects 0.000 claims description 4
- 238000009490 roller compaction Methods 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 238000003801 milling Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 239000004067 bulking agent Substances 0.000 abstract 1
- 229940049654 glyceryl behenate Drugs 0.000 description 18
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 13
- 229960001375 lactose Drugs 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 9
- DJHHDLMTUOLVHY-UHFFFAOYSA-N 1,2,3,4-tetrachlorodibenzodioxine Chemical compound C1=CC=C2OC3=C(Cl)C(Cl)=C(Cl)C(Cl)=C3OC2=C1 DJHHDLMTUOLVHY-UHFFFAOYSA-N 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 229960004354 tegaserod maleate Drugs 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229910002012 Aerosil® Inorganic materials 0.000 description 4
- -1 PrecirolT"" Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 3
- 108091005482 5-HT4 receptors Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920003085 Kollidon® CL Polymers 0.000 description 2
- 206010054048 Postoperative ileus Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- CPDDZSSEAVLMRY-FEQFWAPWSA-N tegaserod maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 CPDDZSSEAVLMRY-FEQFWAPWSA-N 0.000 description 2
- IKBKZGMPCYNSLU-UHFFFAOYSA-N 1-[(5-methoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine Chemical compound C1=C(OC)C=C2C(C=NNC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01403339.3 | 2001-12-21 | ||
| EP01403339A EP1321142A1 (en) | 2001-12-21 | 2001-12-21 | Solid pharmaceutical composition for oral administration of Tegaserod |
| PCT/EP2002/014674 WO2003053432A1 (en) | 2001-12-21 | 2002-12-20 | 5ht4 partial agonist pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2470668A1 CA2470668A1 (en) | 2003-07-03 |
| CA2470668C true CA2470668C (en) | 2011-07-05 |
Family
ID=8183045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2470668A Expired - Fee Related CA2470668C (en) | 2001-12-21 | 2002-12-20 | 5ht4 partial agonist pharmaceutical compositions |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20050106236A1 (enExample) |
| EP (2) | EP1321142A1 (enExample) |
| JP (1) | JP4718776B2 (enExample) |
| KR (1) | KR100980144B1 (enExample) |
| CN (1) | CN100464749C (enExample) |
| AR (1) | AR037937A1 (enExample) |
| AT (1) | ATE320807T1 (enExample) |
| AU (1) | AU2002361198B2 (enExample) |
| BR (1) | BR0215148A (enExample) |
| CA (1) | CA2470668C (enExample) |
| CO (1) | CO5640102A2 (enExample) |
| CY (1) | CY1105559T1 (enExample) |
| DE (1) | DE60210139T2 (enExample) |
| DK (1) | DK1458377T3 (enExample) |
| EC (1) | ECSP105163A (enExample) |
| EG (1) | EG24194A (enExample) |
| ES (1) | ES2258171T3 (enExample) |
| HU (1) | HU226589B1 (enExample) |
| IL (2) | IL162451A0 (enExample) |
| MX (1) | MXPA04006157A (enExample) |
| MY (1) | MY139546A (enExample) |
| NO (1) | NO20042779L (enExample) |
| NZ (1) | NZ533585A (enExample) |
| PE (1) | PE20030872A1 (enExample) |
| PL (1) | PL369509A1 (enExample) |
| PT (1) | PT1458377E (enExample) |
| RU (1) | RU2322978C2 (enExample) |
| SI (1) | SI1458377T1 (enExample) |
| TW (1) | TWI260221B (enExample) |
| WO (1) | WO2003053432A1 (enExample) |
| ZA (1) | ZA200404467B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL200132B1 (pl) * | 1998-08-21 | 2008-12-31 | Novartis Ag | Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| DE602004007105T2 (de) | 2003-01-28 | 2008-02-28 | Microbia Inc., Cambridge | Zusammensetzung zur behandlung von gastrointestinalen störungen |
| WO2004085393A1 (en) * | 2003-03-25 | 2004-10-07 | Hetero Drugs Limited | Novel crystalline forms of tegaserod maleate |
| WO2004104577A2 (en) * | 2003-05-21 | 2004-12-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4) |
| AR045081A1 (es) * | 2003-07-24 | 2005-10-12 | Novartis Ag | Modificaciones estables de maleato de hidrogeno de tegaserod |
| PT1663182E (pt) | 2003-09-12 | 2013-03-14 | Amgen Inc | Formulação de dissolução rápida de cinacalcet hcl |
| US20050165085A1 (en) * | 2003-12-16 | 2005-07-28 | Marioara Mendelovici | Polymorphic forms of tegaserod base and salts thereof |
| CZ298399B6 (cs) * | 2005-05-02 | 2007-09-19 | Zentiva, A. S. | Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu) |
| US20070259052A1 (en) | 2006-05-05 | 2007-11-08 | Shire International Licensing B.V. | Assay for lanthanum hydroxycarbonate |
| ES2393885T7 (es) | 2007-06-04 | 2014-01-30 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP3351248B1 (en) | 2008-12-31 | 2021-06-09 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CA2880338A1 (en) | 2012-08-21 | 2014-02-27 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| KR102287207B1 (ko) | 2013-04-12 | 2021-08-09 | 알데릭스, 인코포레이티드 | Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법 |
| CN104922083B (zh) * | 2015-04-15 | 2017-12-22 | 湖南尔康湘药制药有限公司 | 磺胺嘧啶片及其制备方法 |
| EA036204B1 (ru) * | 2015-10-16 | 2020-10-14 | Нобел Илач Санайи Ве Тиджарет А.Ш. | Фармацевтические композиции нилотиниба гидрохлорида |
| JP2020505333A (ja) | 2017-01-09 | 2020-02-20 | アルデリックス， インコーポレイテッド | Ｎｈｅ媒介性アンチポートの阻害薬 |
| CN110267944B (zh) | 2017-01-09 | 2024-03-08 | 阿德利克斯股份有限公司 | 可用于治疗胃肠道病症的化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0820586A (ja) * | 1994-07-05 | 1996-01-23 | Sanwa Kagaku Kenkyusho Co Ltd | １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途 |
| IL117438A (en) * | 1995-03-16 | 2001-12-23 | Lilly Co Eli | Indazolecarboxamides, their preparation and pharmaceutical compositions containing them |
| JPH09194374A (ja) * | 1995-11-14 | 1997-07-29 | Taisho Pharmaceut Co Ltd | 消化器疾患治療剤 |
| ATE220543T1 (de) * | 1996-04-23 | 2002-08-15 | Janssen Pharmaceutica Nv | Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid |
| US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
| PL200132B1 (pl) * | 1998-08-21 | 2008-12-31 | Novartis Ag | Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu |
| US6465502B1 (en) * | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
| AU3574500A (en) * | 1999-03-25 | 2000-10-16 | Yuhan Corporation | Rapidly disintegrable tablet for oral administration |
| DE60039357D1 (de) * | 1999-08-03 | 2008-08-14 | Lilly Icos Llc | Pharmazeutische zusammensetzung enthaltend tadalafil |
-
2001
- 2001-12-21 EP EP01403339A patent/EP1321142A1/en not_active Withdrawn
-
2002
- 2002-12-17 EG EG2002121358A patent/EG24194A/xx active
- 2002-12-19 TW TW091136675A patent/TWI260221B/zh not_active IP Right Cessation
- 2002-12-19 AR ARP020105024A patent/AR037937A1/es not_active Application Discontinuation
- 2002-12-20 PT PT02796711T patent/PT1458377E/pt unknown
- 2002-12-20 DE DE60210139T patent/DE60210139T2/de not_active Expired - Lifetime
- 2002-12-20 DK DK02796711T patent/DK1458377T3/da active
- 2002-12-20 EP EP02796711A patent/EP1458377B1/en not_active Expired - Lifetime
- 2002-12-20 CN CNB028255321A patent/CN100464749C/zh not_active Expired - Fee Related
- 2002-12-20 CA CA2470668A patent/CA2470668C/en not_active Expired - Fee Related
- 2002-12-20 ES ES02796711T patent/ES2258171T3/es not_active Expired - Lifetime
- 2002-12-20 PL PL02369509A patent/PL369509A1/xx not_active Application Discontinuation
- 2002-12-20 HU HU0402492A patent/HU226589B1/hu not_active IP Right Cessation
- 2002-12-20 SI SI200230334T patent/SI1458377T1/sl unknown
- 2002-12-20 BR BR0215148-0A patent/BR0215148A/pt not_active IP Right Cessation
- 2002-12-20 AU AU2002361198A patent/AU2002361198B2/en not_active Ceased
- 2002-12-20 US US10/499,721 patent/US20050106236A1/en not_active Abandoned
- 2002-12-20 NZ NZ533585A patent/NZ533585A/en not_active IP Right Cessation
- 2002-12-20 AT AT02796711T patent/ATE320807T1/de active
- 2002-12-20 IL IL16245102A patent/IL162451A0/xx active IP Right Grant
- 2002-12-20 MX MXPA04006157A patent/MXPA04006157A/es active IP Right Grant
- 2002-12-20 WO PCT/EP2002/014674 patent/WO2003053432A1/en not_active Ceased
- 2002-12-20 RU RU2004122631/15A patent/RU2322978C2/ru not_active IP Right Cessation
- 2002-12-20 JP JP2003554189A patent/JP4718776B2/ja not_active Expired - Fee Related
- 2002-12-20 MY MYPI20024825A patent/MY139546A/en unknown
- 2002-12-20 KR KR1020047009594A patent/KR100980144B1/ko not_active Expired - Fee Related
-
2003
- 2003-01-06 PE PE2003000004A patent/PE20030872A1/es not_active Application Discontinuation
-
2004
- 2004-06-07 ZA ZA200404467A patent/ZA200404467B/en unknown
- 2004-06-10 IL IL162451A patent/IL162451A/en not_active IP Right Cessation
- 2004-07-01 NO NO20042779A patent/NO20042779L/no not_active Application Discontinuation
- 2004-07-15 CO CO04067463A patent/CO5640102A2/es not_active Application Discontinuation
-
2006
- 2006-05-04 CY CY20061100579T patent/CY1105559T1/el unknown
-
2008
- 2008-10-07 US US12/287,232 patent/US20090104263A1/en not_active Abandoned
-
2010
- 2010-06-16 EC EC2010005163A patent/ECSP105163A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2470668C (en) | 5ht4 partial agonist pharmaceutical compositions | |
| EP1058538B9 (en) | Fast disintegrating tablets | |
| CA2272586C (en) | Rapidly disintegrable pharmaceutical composition | |
| US6599530B2 (en) | Oral compacted composition comprising catechol derivatives | |
| NZ532829A (en) | Film coated solid pharmaceutical compositions comprising sumatriptin for treating pain | |
| EP0266707B1 (en) | Sustained release labetalol tablet | |
| HU200924B (en) | Process for producing pharmaceutical compositions comprising terfenadine | |
| US4940580A (en) | Sustained release labetalol tablets | |
| WO2006000583A2 (en) | Oral sustained release formulation of tedisamil with gastric retention properties | |
| AU2002333235B2 (en) | Pharmaceutical formulation containing an LTB4 antagonist | |
| WO2005092293A1 (en) | Formulations of metformin | |
| US5217965A (en) | Stabilized solid dosage forms of choline metal carboxymethylcellulose salicylate compositions | |
| EP1906931B1 (en) | Improved pharmaceutical composition containing ace inhibitor and method for the preparation thereof | |
| US20030229101A1 (en) | Tablets comprising ciprofloxacin hydrochloride | |
| EP2403500A2 (en) | Stable olanzapine tablets and the process for its preparation | |
| EP3843702A1 (en) | Immediate release fixed-dose combination of memantine and donepezil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20131220 |